SCHEMBL11945347

SCHEMBL11945347

O=c1c(OCc2ccccc2)c(N2CCN(S(=O)(=O)Cc3cccnc3)CC2)cnn1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.52
▸ ALDH1A1 P00352 4/20 0.46
▸ DCTPP1 Q9H773 1/20 0.46
▸ MAPK14 Q16539 1/20 0.42
▸ HSD11B1 P28845 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ NPC1 O15118 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ PRMT5 O14744 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944410 0.93 MAPT (0.57) MAPTALDH1A1DCTPP1MAPK14HSD11B1
SCHEMBL11945348 0.87 MAPT (0.52) MAPTALDH1A1DCTPP1MAPK14HSD11B1
SCHEMBL11945317 0.87 MAPT (0.49) MAPTALDH1A1DCTPP1HSD11B1POLB
SCHEMBL11943928 0.85 MAPT (0.52) MAPTALDH1A1DCTPP1MAPK14HSD11B1
SCHEMBL11944393 0.85 MAPT (0.53) MAPTALDH1A1DCTPP1POLBSMN1; SMN2
SCHEMBL11944072 0.84 MAPT (0.52) MAPTALDH1A1DCTPP1MAPK14HSD11B1
SCHEMBL11945342 0.84 MAPT (0.48) MAPTALDH1A1DCTPP1MAPK14POLB
SCHEMBL11944240 0.84 MAPT (0.61) MAPTALDH1A1DCTPP1POLBNPC1
SCHEMBL11944525 0.84 ALDH1A1 (0.65) MAPTALDH1A1DCTPP1MAPK14POLB
SCHEMBL11945328 0.83 MAPT (0.48) MAPTALDH1A1DCTPP1HSD11B1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885DCTPP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback